期刊文献+

AA、MDS、IDA患者血清促红细胞生成素水平变化及与Hb、RBC的关系 被引量:2

下载PDF
导出
摘要 目的观察再生障碍性贫血(AA)、骨髓增生异常综合征(MDS)、缺铁性贫血(IDA)患者血清促红细胞生成素(EPO)的水平变化及与Hb、RBC的关系。方法 AA患者12例、MDS患者8例、IDA患者5例,采用放射免疫法测定患者血清EPO水平,并与19例健康对照者比较,同时检测患者Hb、RBC,骨髓穿刺检查了解骨髓增生程度,分析血清EPO水平与Hb、RBC的相关性,同时分析骨髓增生程度与EPO水平的关系。结果 10例AA、6例MDS、4例IDA患者血清EPO水平均明显高于健康对照者(P均<0.01);AA者EPO与Hb、RBC均呈负相关(r分别为-0.76、-0.71,P均<0.01),MDS者EPO与Hb、RBC均呈负相关(r分别为-0.67、-0.69,P均<0.01),IDA者EPO与Hb、RBC均呈负相关(r分别为-0.83、-0.55,P均<0.01)。骨髓增生低下组14例,血清EPO水平均明显升高;骨髓增生活跃组11例,其中9例血清EPO水平升高。骨髓增生活跃、低下与血清EPO无相关性(P均>0.05)。结论 AA、MDS、IDA患者血清EPO水平明显升高;血清EPO水平与H6、RBC呈明显负相关关系。骨髓增生程度与血清EPO水平无明显相关性。
出处 《山东医药》 CAS 北大核心 2015年第17期85-86,共2页 Shandong Medical Journal
  • 相关文献

参考文献7

二级参考文献29

  • 1李蓉生,张之南.基因重组人红细胞生成素治疗非肾性贫血[J].中华血液学杂志,1993,14(5):229-231. 被引量:9
  • 2韩冰,李淑兰,沈悌,石远凯,何小慧,朱军,林宁静.血液系统恶性肿瘤患者体内红细胞生成素水平的研究[J].中华血液学杂志,2006,27(8):543-545. 被引量:12
  • 3Basu S, Banerjee D, Ghosh M, et al. Erythrocyte membrance defects and asymmetry in paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome [ J]. Haematology, 2010, 15(4) :236-239.
  • 4Szenajch J, Wcislo G, Jeong J Y, et al. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells from clinic to bench-a critical review[J]. Biochim Biophy Acta, 2010, 1806( 1 ) :82-95.
  • 5Khosroshahi H T, Shoja M M, Tubbs R S. Serum eryth- ropoiefin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients[J]. Tansplant Procology, 2007, 39 (4) : 1051- 1053.
  • 6Stein R S. The role of erythropoietin in the anemia of myelodysplastic syndromes [J].Clin Lymphoma, 2003, 4 ( 1 ) :36-40.
  • 7Kornblau S M, Mccue D, Singh N. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia[J]. Blood, 2010, 38(3) :188-191.
  • 8Jadersten M, Montgomery S M, Dybedal I, et al. Long- term outcome of treatment of anemia in MDS with erythropoietin and G-CSF [ J ]. Blood, 2005, 106 ( 3 ) : 803- 811.
  • 9Jonckheere S, Dierick J, Vanhouteghern H. Erythrocyte indices in the assessment of iron status in dialysis-dependent patients with end-stage renal disease on continuous erythropoietin activator versus epoetin beta therapy[ J ]. Haematology, 2010, 124( 1 ) :27-33.
  • 10Pierri I, Balleari E, Olcese F. High dose of r-EPO(40 000 IU)once a week is highly effective in a selected cohort of MDS patients with basal EPO level < 250mu/ml, IPSS score ≤ 1.5 and low transfusional need [ J ]. Leukemia Research, 2007, 31 ( 1 ) : 140.

共引文献21

同被引文献9

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部